You are here

  • Home
  • Archive
  • Volume 24, Issue Suppl 1
  • CP-098 Economic impact of implementation of natalizumab use with extended interval dosing in patients with relapsing remitting multiple sclerosis

Article metrics

Article menu
Download PDFPDF
Clinical pharmacy
CP-098 Economic impact of implementation of natalizumab use with extended interval dosing in patients with relapsing remitting multiple sclerosis

 

Online download statistics by month:

Online download statistics by month: February 2017 to September 2024

AbstractFullPdf
Feb 2017100
Mar 2017304
May 20171100
Jun 20171001
Jul 20171000
Aug 20171204
Sep 2017800
Oct 2017200
Nov 20171200
Dec 20171400
Jan 2018800
Feb 20181000
Mar 20181200
Apr 20181000
May 20183201
Jun 2018800
Jul 20181000
Aug 2018400
Sep 2018200
Oct 2018200
Nov 20181800
Dec 20183000
Jan 20191200
Feb 2019400
Mar 2019400
Apr 2019401
May 2019600
Jun 2019800
Jul 2019600
Aug 20192800
Sep 2019400
Oct 20192000
Dec 2019600
Jan 2020200
Feb 2020200
Mar 2020200
Apr 2020400
Jun 2020600
Jul 2020800
Aug 20202400
Sep 2020600
Oct 20207000
Nov 20201401
Dec 2020200
Jan 2021700
Feb 2021200
Mar 2021400
May 2021100
Nov 2021400
Dec 20211200
Jan 2022200
Feb 2022200
Mar 2022400
Apr 2022400
May 2022400
Jun 20222800
Jul 20221200
Aug 2022400
Sep 2022600
Oct 2022200
Nov 20221400
Dec 2022600
Jan 2023400
Feb 2023400
Mar 2023900
May 2023400
Jun 2023200
Jul 2023200
Sep 2023200
Nov 2023400
Dec 20231000
Jan 2024200
Feb 2024600
Mar 2024400
Apr 2024600
May 2024400
Jun 2024400
Jul 2024400
Aug 2024500
Sep 2024600
Total671012